Champions Oncology Sustainability Profile
Champions Oncology, a leading player in the biotechnology industry, is headquartered in China (CN) and operates extensively across North America and Europe. Founded in 2010, the company has made significant strides in advancing personalised cancer treatment through its innovative technology platforms. Specialising in the development of patient-derived xenograft (PDX) models, Champions Oncology offers unique solutions that enable oncologists to tailor therapies based on individual tumour characteristics. This approach not only enhances treatment efficacy but also optimises patient outcomes. With a strong market position, Champions Oncology has garnered recognition for its contributions to cancer research and personalised medicine, solidifying its reputation as a trusted partner in the fight against cancer.
DitchCarbon Score
How does Champions Oncology's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Champions Oncology's score of 26 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Champions Oncology's reported carbon emissions
Champions Oncology, headquartered in CN, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas emissions. The company has committed to a 42% reduction in Scope 1 and Scope 2 emissions by 2030, using 2020 as the baseline year. This target has been validated through the Science Based Targets initiative (SBTi) and is aligned with the goal of limiting global warming to 1.5°C. While specific emissions data for the most recent year is not available, Champions Oncology's commitment to measure and reduce its Scope 3 emissions further demonstrates its dedication to comprehensive climate action. The targets are part of a broader strategy to enhance sustainability within the pharmaceuticals, biotechnology, and life sciences sector. Champions Oncology's initiatives reflect a proactive approach to climate responsibility, positioning the company as a leader in environmental stewardship within its industry.
How Carbon Intensive is Champions Oncology's Industry?
How Carbon Intensive is Champions Oncology's Location?
Champions Oncology's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Champions Oncology has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
